The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, single-center, fixed dose, open label trial to explore the safety,
tolerability and efficacy of a 25mg dose of psilocybin in cancer patients with MDD. The study
population will include adult men and women, 18 years of age or above, with MDD, diagnosed
with a malignant neoplasm. MDD is defined as those who meet DSM 5 diagnostic criteria for a
single or recurrent episode of MDD without psychotic features. A diagnosis of a malignant
neoplasm is defined as having a diagnostic code from C00 to C97 according to the ICD-10.